Selank is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, where it was synthesized as a modified derivative of tuftsin — an endogenous immune-regulating tetrapeptide found in blood. Unlike Epithalon or MOTS-c, which live in the longevity research space, Selank occupies a distinct niche: clinically approved in Russia as an anxiolytic, with a two-decade track record in human use there.
The regulatory status matters. In Russia, Selank is marketed as a pharmaceutical treatment for anxiety and stress disorders, meaning it has undergone clinical trial frameworks, post-marketing surveillance, and dose-standardization typical of approved drugs. In the West, it remains research-only. This gap between regulatory contexts shapes both the data available and the appropriate framing for readers unfamiliar with Russian pharmacopoeia.
Mechanism
Selank modulates GABAergic and serotonergic neurotransmission — the same targets as benzodiazepines and SSRIs, respectively. But unlike those drug classes, Selank is reported to achieve anxiolytic effects without sedation and without withdrawal liability on discontinuation. The mechanistic explanation involves expression-level changes in enkephalin and BDNF (brain-derived neurotrophic factor), along with modulation of neuropeptide Y, suggesting effects beyond simple GABA potentiation.
The tuftsin ancestry is also relevant. Tuftsin is an immunomodulating peptide that enhances monocyte and neutrophil phagocytosis. Selank retains some of this immunomodulatory activity, with published reports of NK-cell activation and mild shifts in Th1/Th2 balance. Whether the immune component contributes meaningfully to anxiolytic effects is unclear — most of the clinical data focuses on mood and anxiety endpoints, not immune measures.
Pharmacokinetics
Selank is administered intranasally in clinical and research protocols — a route that achieves rapid bioavailability with direct access to the CNS, potentially bypassing first-pass hepatic metabolism. Plasma half-life is short (minutes), consistent with other neuropeptides, but CNS effects are reported to persist for hours, suggesting either receptor-level persistence or local CNS depot effects not yet fully characterized.
Intranasal dosing is well-tolerated in the published Russian trials, with minimal systemic side effects at therapeutic doses. Bioavailability varies with nasal mucosa integrity and technique, a consideration for protocol-to-protocol reproducibility.
